Dr. Senu K. Apewokin, MD

Dr. Apewokin practices at UC Medical Center in Cincinnati, Ohio.

Dr. Apewokin's NPI, 1730370958, was assigned on August 5, 2007. Dr. Apewokin graduated from University of Ghana Medical School in 2002. Dr. Apewokin holds Ohio license 35 120629.

Dr. Apewokin's primary practice is UC Medical Center, at 3188 Bellevue Ave, Cincinnati, OH 45219 in Hamilton County. The practice phone is (513) 584-1000.

Dr. Apewokin's primary practice is UC Medical Center in Cincinnati, Ohio. Dr. Apewokin is also affiliated with University of Cincinnati Medical Center. The medical group on file is University of Cincinnati Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Apewokin practices. Vendor and product names are available with a free account.

Infectious disease is Dr. Apewokin's primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Apewokin is board certified in infectious disease by the American Board of Internal Medicine. Dmand AI has Dr. Apewokin's licenses on file in 5 states: Ohio, Arkansas, Arizona, Alabama and Pennsylvania.

Dmand AI lists hiv/aids, joint or bone infection and UTI among the conditions Dr. Apewokin treats.

CMS data shows 12 Medicare services from Dr. Apewokin across 1 procedure code in 2024, for 39 Medicare patients. Medicare paid $1,172 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 39 Medicare patients who saw Dr. Apewokin in 2024. The largest group is 65 to 74, with 26 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 4.11, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Apewokin's median patient age at 59, with 44% women.

In 2024, Dr. Apewokin wrote 235 Medicare Part D claims for 22 patients. 46% of them were for generic drugs. CMS names the drug for 143 of them, across 9 drugs with 11 or more claims each, at $289,984 in total drug cost. In 2023, CMS named 101 claims across 6 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Apewokin for performance year 2024, reported as part of a group. Dr. Apewokin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 39 papers to Dr. Apewokin, published from 2012 to 2025. 2018 was the busiest year, with 4. The most frequent topics are Hematopoietic Stem Cell Transplantation, Kidney Transplantation and Multiple Myeloma. Dr. Apewokin has published most often in Transpl Infect Dis. Dr. Apewokin's most frequent co-authors are Elias Anaissie, MD, Emily A. Blumberg, MD and Elizabeth A. Coleman, MD.

Dmand AI links Dr. Apewokin to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Acquired Immunodeficiency Syndrome, Slow Virus Diseases and Multiple Myeloma. Johns Hopkins University sponsors the most, 2.

CMS Open Payments shows 35 general payments to Dr. Apewokin from 6 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 52% of the total. Aimmune Therapeutics, Inc. paid the most, $10,093.

Dr. Apewokin graduated from University of Ghana Medical School in 2002. Dr. Apewokin is a member of ACP.

Dr. Apewokin is in network with 21 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.